UNSPSC 51111853: Inocoterone

This classification denotes an anti-androgen with the molecular formula C18H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ONU02D116S, chemically known as (3S,3aS,9aS,9bS)-6-ethyl-3-hydroxy-3a-methyl-2,3,4,5,8,9,9a,9b-octahydro-1H-cyclopenta[a]naphthalen-7-one but generally known as inocoterone, which bears US NIH Compound Identifier 11776794. European Medicines Agency schedules inocoteronein its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08189MIG.

Most nations schedule inocoterone under HS 29379000 and SITC 54155. As of Q4 2014, INOCOTERONE remains the US FDA Preferred Term for this commodity. SMILES: CCC1=C2CCC3(C(C2CCC1=O)CCC3O)C.

UNSPSC 51111853 Inocoterone is a Commodity code for a specific pharmaceutical active ingredient used in multi-source generic drug formulations. State and local governments procure this ingredient as part of broader pharmaceutical supply agreements, particularly through cooperative purchasing vehicles that consolidate demand across multiple jurisdictions. The work involves sourcing and supplying pharmaceutical-grade inocoterone to authorized wholesalers and distributors who then deliver finished pharmaceutical products to state and local facilities, hospitals, correctional institutions, and other government healthcare operations. Issuing bodies include state departments of administration and health, multistate cooperative purchasing alliances, and affiliated local government health agencies that participate in shared procurement agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 (RFP S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026. The solicitation encompasses participating states and local government facilities, including Oregon. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), and demonstrate pricing flexibility through multiple formats including flat price, net price structures, or WAC-minus arrangements. Products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026 for a two-year initial term. Evaluation weighting emphasizes price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee.